Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, shares final results of a Phase Ib feasibility/safety study on short-duration fixed-volume isatuximab infusion combination therapy for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).